BIOMEA FUSION INC (BMEA) Stock Overview
USA - NASDAQ:BMEA - US09077A1060 - Common Stock
BMEA Key Statistics, Chart & Performance
The current stock price of BMEA is 2.02 USD. In the past month the price increased by 16.09%. In the past year, price decreased by -76.62%.
BMEA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.42 | 382.04B | ||
| AMGN | AMGEN INC | 12.52 | 147.02B | ||
| GILD | GILEAD SCIENCES INC | 14.32 | 137.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 100.34B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.6 | 60.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.46B | ||
| ARGX | ARGENX SE - ADR | 81.16 | 46.04B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.72 | 38.90B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.86B | ||
| BIIB | BIOGEN INC | 8.97 | 21.06B |
Related stock screener links
About BMEA
Company Profile
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 63 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Company Info
BIOMEA FUSION INC
1599 Industrial Road
San Carlos CALIFORNIA US
Employees: 63
Phone: 16509809099
BIOMEA FUSION INC / BMEA FAQ
What is the stock price of BIOMEA FUSION INC today?
The current stock price of BMEA is 2.02 USD. The price increased by 3.06% in the last trading session.
What is the ticker symbol for BIOMEA FUSION INC stock?
The exchange symbol of BIOMEA FUSION INC is BMEA and it is listed on the Nasdaq exchange.
On which exchange is BMEA stock listed?
BMEA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOMEA FUSION INC stock?
14 analysts have analysed BMEA and the average price target is 7.43 USD. This implies a price increase of 267.89% is expected in the next year compared to the current price of 2.02. Check the BIOMEA FUSION INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOMEA FUSION INC worth?
BIOMEA FUSION INC (BMEA) has a market capitalization of 120.21M USD. This makes BMEA a Micro Cap stock.
How many employees does BIOMEA FUSION INC have?
BIOMEA FUSION INC (BMEA) currently has 63 employees.
What are the support and resistance levels for BIOMEA FUSION INC (BMEA) stock?
BIOMEA FUSION INC (BMEA) has a support level at 1.91 and a resistance level at 2.03. Check the full technical report for a detailed analysis of BMEA support and resistance levels.
Should I buy BIOMEA FUSION INC (BMEA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BMEA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BMEA, evaluating the profitability, health, valuation and growth aspects
- BIOMEA FUSION INC (BMEA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOMEA FUSION INC (BMEA) Sales and EPS estimates to see what analysts future expectations are.
- BIOMEA FUSION INC (BMEA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOMEA FUSION INC (BMEA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOMEA FUSION INC (BMEA) Stock Chart to make your own analysis
- BIOMEA FUSION INC (BMEA) Latest news and press-releases to stay up to date.
Does BIOMEA FUSION INC (BMEA) stock pay dividends?
BMEA does not pay a dividend.
When does BIOMEA FUSION INC (BMEA) report earnings?
BIOMEA FUSION INC (BMEA) will report earnings on 2025-10-29, after the market close.
What is the Price/Earnings (PE) ratio of BIOMEA FUSION INC (BMEA)?
BIOMEA FUSION INC (BMEA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.03).
What is the Short Interest ratio of BIOMEA FUSION INC (BMEA) stock?
The outstanding short interest for BIOMEA FUSION INC (BMEA) is 14.94% of its float. Check the ownership tab for more information on the BMEA short interest.
BMEA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BMEA. When comparing the yearly performance of all stocks, BMEA is a bad performer in the overall market: 94.11% of all stocks are doing better.
BMEA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BMEA. While BMEA seems to be doing ok healthwise, there are quite some concerns on its profitability.
BMEA Financial Highlights
Over the last trailing twelve months BMEA reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 22.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -153.21% | ||
| ROE | -407.46% | ||
| Debt/Equity | 0 |
BMEA Forecast & Estimates
14 analysts have analysed BMEA and the average price target is 7.43 USD. This implies a price increase of 267.89% is expected in the next year compared to the current price of 2.02.